Clinical trials: Tace
Hepatocellular Carcinoma, Neuroendocrine Tumors
Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery
The goal of this clinical trial is to compare CT scan of the coverage of tumors treated with TACE using End Hole catheters to those treated with the TriNav catheter that alters tissue pressure.
- Trial name
- Trinav (NCT06204159)
- Testing
- TACE Catheters
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Hepatocellular Carcinoma
TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC
The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with PD-1/PD-L1 Inhibitors and molecular target therapies in patients with Intermediate-stage…
- Trial name
- CHANCE2202 (NCT05332496)
- Testing
- PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE
- Where
- 2 sites in China
- Volunteers
- 941 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma, Hepatic Chemotherapy
TACE Combined Surgery for the Resectable Huge HCC
Huge hepatocellular carcinoma (HCC) is defined as a tumor with a maximum diameter greater than 10 cm. With advancements in surgical techniques, hepatectomy can be performed safely in some patients with huge HCC without vascular…
- Conditions
- Hepatocellular Carcinoma, Hepatic Chemotherapy, Liver Cancer, Surgery
- Trial name
- NCT06898398
- Testing
- TACE, Surgery
- Where
- China
- Volunteers
- 326 people
- Sponsor
- Sun Yat-sen University
Tislelizumab, Lenvatinib
Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular Carcinoma
ICIs combined with AATDs have gradually become the mainstream treatment modality for advanced hepatocellular carcinoma, and more related clinical trials are underway.
- Conditions
- Tislelizumab, Lenvatinib, TACE, Advanced Unresectable Hepatocellular Carcinoma
- Trial name
- NCT05131698
- Testing
- Tislelizumab and Lenvatinib
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Cancer Hospital of Guangxi Medical University
Unresectable Metastatic Colo-rectal Cancer
Chemoembolization, Irinotecan Bead, Second Line Chemotherapy Treatment of Unresectable Metastatic Colorectal Cancer
The primary objective of this study is to evaluate the safety and efficacy of Irinotecan Bead in combination with intravenous chemotherapy versus intravenous chemotherapy alone in the treatment of unresectable liver metastases in…
- Trial name
- PARAGON (NCT00816777)
- Testing
- Chemoembolization with irinotecan Bead, Irinotecan
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Generic Devices Consulting, Inc.
Hepatecellular Carcinoma, Liver Injury
HAIC vs. TACE Combined With ICIs and TKIs in Intermediate-to-Advanced HCC: A Multicenter Study on Liver Injury and Survival
The purpose of this study is to compare the liver injury induced by HAIC combined with PD-1/PD-L1 inhibitors and TKIs versus triple therapy with TACE in the treatment of patients with advanced HCC; to compare the efficacy of the…
- Conditions
- Hepatecellular Carcinoma, Liver Injury, HAIC(Hepatic Artery Infusion Chemotherapy), TACE(Transcatheter Arterial Chemoembolization)
- Trial name
- NCT07277192
- Where
- China
- Volunteers
- 562 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Unresectable Hepatocellular Carcinoma
TACE With Thermosensitive Nanogel Versus Embosphere for HCC
To verify the safety and efficacy of TACE withThermosensitive Nanogel Embolic Agent for HCC.
- Trial name
- NCT06593964
- Testing
- Thermosensitive Nanogel Embolic Agent
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Zhongda Hospital
Hepato Cellular Carcinoma (HCC)
Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma
IMPACT-TACE is an investigator-initiated, prospective, multicenter, randomized, double-blinded, interventional trial to test the hypothesis that the simultaneous application of doxorubicin with the ABCB1 inhibitor nicardipine…
- Trial name
- IMPACT-TACE (NCT07302919)
- Testing
- DEB-DoxNic-TACE, current standard of care
- Where
- 3 sites in Switzerland
- Volunteers
- 152 people
- Sponsor
- University Hospital, Basel, Switzerland
Hepatocellular Carcinoma, Transarterial Chemoembolization
TACE-HAIC Plus Lenvatinib for Patients With Unresectable HCC: an Open-label, Single-arm, Phase 2 Trial
Hepatocellular carcinoma (HCC) is one of the most commonly malignant tumors around the world. Hepatic resection or liver transplantation is the radical method to cure the disease.
- Trial name
- Thalen (NCT04531228)
- Testing
- TACE-HAIC plus lenvatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Yunfei Yuan
Hepatocellular Carcinoma
HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure
This study is a prospective, randomized controlled, multicenter clinical study. The purpose of this study is to explore the efficacy and safety of hepatic artery infusion chemotherapy (HAIC) combined with second-line regorafenib…
- Trial name
- NCT05233358
- Testing
- Hepatic Artery Infusion Chemotherapy, Transarterial Chemoembolization, Regorafenib
- Volunteers
- 176 people
- Sponsor
- The Central Hospital of Lishui City
Carcinoma, Hepatocellular
TACE Combined With Synchronous Radiofrequency /Microwave Ablation to Treat Large and Huge Hepatocellular Carcinoma
It is a prospective and multi-center clinical research in China to compare the efficacy, safety and related impact factors between TACE alone and TACE combined with synchronous multi-point MWA/RFA for large and huge liver cancer.
- Trial name
- NCT02630108
- Testing
- Thermal Ablation, EADM, Ultra-fluid lipiodol
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma, TACE
Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence
A single-arm, open-label clinical trial to assess the effects and safety of anlotinib hydrochloride combined with transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma(HCC) patients at high risk of post…
- Conditions
- Hepatocellular Carcinoma, TACE, Anlotinib
- Trial name
- ALTER-H-004 (NCT04213118)
- Testing
- Anlotinib Hydrochloride, TACE
- Where
- 4 sites in China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Hepatocellular Carcinoma, Portal Vein Tumor Thrombosis
Irradiation Stent Placement Plus TACE for HCC and PVTT
The study is a multicenter, randomized (1:1), open-label, parallel-arm, Phase 3 clinical trial to evaluate the efficacy and safety of portal irradiation stent placement plus TACE compared to sorafenib plus TACE in patients with…
- Trial name
- NCT03730675
- Testing
- Portal irradiation stent placement, TACE, Sorafenib
- Where
- China
- Volunteers
- 308 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma
TACE Combined with Sintilimab Plus Bevacizumab Biosimilar in Patients with Advanced Hepatocellular Carcinoma (TASK-02)
The objective of this study is to evaluate the efficacy and safety of TACE combined with Sintilimab plus bevacizumab biosimilar in patients with advanced hepatocellular carcinoma as first-line therapy.
- Trial name
- NCT04954794
- Testing
- Sintilimab, TACE
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Fudan University
Potentially Resection, Hepatocellular Carcinoma
TACE-HAIC vs. HAIC for Potentially Resectable HCC
Hepatocellular carcinoma (HCC) is one of the most commonly malignant tumors around the world. Hepatic resection or liver transplantation is the radical method to cure the disease.
- Trial name
- NCT03591705
- Testing
- TACE-HAIC, HAIC
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Sun Yat-sen University
Liver Cancer
Clinical Trial of Cinobufacini Combined With Transarterial Chemoembolization (TACE) on Primary Liver Cancer
The clinical trail of Cinobufacini combined with TACE on primary liver cancer.The trail is randomized controled.Patients are diagnosed primary liver cancer based on pathology or cell biology.They are randomized into 2 groups:both…
- Trial name
- NCT03843229
- Testing
- Cinobufacini injection, Transarterial Chemoembolization(TACE), cinobufacini tablet
- Where
- China
- Volunteers
- 90 people
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
Hepatocellular Carcinoma, Chemoembolization, Therapeutic
TACE+RFA Versus TACE Alone for Intermediate-stage Hepatocellular Carcinoma
The current standard treatment for intermediate-stage HCC (BCLC stage B) is transcatheter arterial chemoembolization (TACE) alone. The combination of TACE with RFA has also reported to be an effective treatment for HCC.
- Conditions
- Hepatocellular Carcinoma, Chemoembolization, Therapeutic, Ablation Techniques, RFA
- Trial name
- TORCH (NCT02435953)
- Testing
- TACE, RFA
- Where
- China
- Volunteers
- 241 people
- Sponsor
- Ming Zhao
Liver Cancer
Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00335829
- Testing
- bevacizumab, chemotherapy, embolization therapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Yale University
HepatoCellular Carcinoma
The Impact on Therapeutic Effect and Tolerance of Treatment for Patients With Hepatocellular Carcinoma in Transcatheter Arterial Chemoembolization (TACE) of Dexamethasone Application: A Random, Double-blind, Controlled, Clinical Trial.
The current random, double-blind, controlled, clinical trial was designed to evaluate the impact on therapeutic effect and tolerance of treatment for patients with hepatocelluclar carcinoma in transcatheter arterial…
- Trial name
- NCT02987907
- Testing
- Dexamethasone, Normal Saline
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Sun Yat-sen University
Inoperable Hepatocellular Carcinoma
MANDARIN (S6371)
To evaluate the efficacy and safety of TheraSphereTM yttrium [90Y] glass microsphere in the Chinese patients with inoperable hepatocellular carcinoma.
- Trial name
- NCT05016245
- Testing
- TheraSphere™ Yttrium-90 Glass Microspheres, conventional Transarterial Chemoembolization(cTACE)
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Boston Scientific Corporation